Erlizumab is a monoclonal antibody targeting integrin β2 (CD18), a protein involved in leukocyte adhesion and migration. This reference antibody is designed for research use, serving as a standard for bioanalytical assays, binding studies, and validation of anti-CD18 therapeutics. It specifically binds to CD18, inhibiting leukocyte attachment and transmigration to sites of inflammation, mimicking the mechanism of the original erlizumab candidate.

Originally developed for modulating immune responses in inflammatory and autoimmune conditions, it has been investigated in ischemia-reperfusion injury (e.g., organ transplantation, acute myocardial infarction) and chronic diseases like multiple sclerosis and rheumatoid arthritis. By blocking CD18 function, it reduces excessive immune activity and tissue damage without broad immunosuppression.

Development of the therapeutic was limited by efficacy and infection risks, but this reference antibody supports ongoing research into adhesion molecule inhibitors. Not for therapeutic use.